Lobaplatin is the third-generation platinum drug that has been shown promising antitumor activity in preclinical studies and clinical trials for multiple human cancers except prostate cancer. In this study, we investigated the role of lobaplatin on prostate cancer progression and the underlying molecular mechanism. We treated a variety of prostate cancer cell lines with different doses of lobaplatin and examined cell cycle progression, cell apoptosis, cell proliferation, and cell migration. Moreover, we also assessed the in-vivo antitumor activity of lobaplatin using xenograft mouse model. Importantly, we further dissected the underlying molecular mechanism by examining the expression of AR and ERG, as well as their downstream targets. We found that lobaplatin arrested cell cycle progression in G2/M phase and trigged cell apoptosis. Lobaplatin also dramatically inhibited cell proliferation and migration in vitro. Consistently, lobaplatin significantly suppressed tumor growth in xenograft mouse model. Mechanistically, the expression of AR and ERG, as well as their downstream targets, was markedly decreased upon treatment with lobaplatin in prostate cancer cells. Altogether, our results suggest that lobaplatin displayed favorable antitumor activity on prostate cancer both in vitro and in vivo, providing molecular basis and rational for using lobaplatin to combat human prostate cancer.
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I N T R O D U C T I O N
Among the six most common cancers in men, prostate cancer is the second leading cause of cancer-related deaths worldwide [1] . It is estimated that more than 26 000 and 60 000 people will die from prostate cancer in the USA and China in 2015, respectively [2, 3] . However, compared to the decreased incidence in the USA, prostate cancer incidence in China is rapidly increased over the past decade [2] . Therefore, it is urgent to develop efficient drugs or strategies for prostate cancer therapy.
Recently, large-scale genomic sequencing profiles revealed that prostate cancer is a heterogeneous disease, driven by various genetic mutations and oncogenic signaling pathways, especially the androgen receptor (AR) signaling pathway [4] [5] [6] . The AR is a ligand-dependent transcription factor that plays a critical role in prostate development and homeostasis by modulating the expression of specific genes involved in cell cycle regulation, growth and apoptosis [7] . Aberrant AR signaling, including amplification and point mutations of AR gene, or overexpression of active AR splicing variants, contributes to prostate cancer initiation and metastasis, as well as resistance to hormone therapy [8] [9] [10] . Another major driver of prostate cancer is gene fusion [11] . Notably, the most common gene fusion is TMPRSS2-ERG that occurs in more than 50% of prostate cancers. Fusion of ERG to TMPRSS2 leads to a dramatic elevation of ERG expression and subsequently promotes cell migration and invasion [12, 13] . Consistently, the TMPRSS2-ERG fusion is frequently associated with the prostate cancer precursor high-grade prostatic intraepithelial neoplasia (HGPIN), further indicating its critical role in prostate cancer development [14] .
Currently, surgery and radiation are common and effective methods for localized prostate cancer. However, more than 20% of patients with localized PrCa will develop metastatic disease even with local therapy. To this end, the emerging androgen deprivation therapy becomes the first-line treatment for metastatic prostate cancer and exhibits promising response in initial stage [15] . However, these patients frequently develop resistance to castration, namely castration-resistant prostate cancer (CRPC) [16] . New therapeutic agents, such as abiraterone and enzalutamide that block the AR signal, are effective for treatment of CRPC [17] . Despite these significant advances in treatments of prostate cancer have been made in the past decades, prostate cancer cells eventually develop resistance and become more aggressive, leading to low survival rates for prostate cancer. Therefore, in addition to androgen deprivation therapy, novel therapeutic approaches are needed to control prostate cancer.
Lobaplatin (D-19466; 1, 2-diammino-methyl-cyclobutaneplatinum (II)-lactate) is a representative of the third-generation platinum drugs and has shown promising antitumor activity in a variety of preclinical models and clinical trials, including breast cancer and small cell lung cancer [18] . Moreover, compared with cisplatin, lobaplatin displays lower toxicity and overcomes resistance to cisplatin in some types of cancers. Therefore, lobaplatin has been approved for the treatment of metastatic breast cancer, chronic myelogenous leukemia and small cell lung cancer in China [19] .
However, whether and how lobaplatin suppresses prostate cancer development is largely unknown. This study aimed to dissect the potential antitumor effects of lobaplatin in treating prostate cancer and the underlying molecular mechanisms. Specifically, we aimed to investigate the effects of lobaplatin on cell cycle, apoptosis, proliferation, migration and tumor growth in prostate cancer cells and xenograft mouse model. We hypothesized that lobaplatin may suppress prostate cancer progression in part by blocking AR and ERG signaling pathways, both of which are major driver of prostate cancer. Cell culture All prostate cancer cell lines, including 22Rv1, LNCaP, VCaP and C4-2, were purchased from American Type Culture Collection (ATCC) and cultured in RPMI (Grand Island, NY, Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA), 2 mM L-glutamine (Gibco, USA), and were maintained in a humidified chamber at 37°C containing 5% CO 2 .
M A T E R I A L S A N D M E T H O D S

Materials
Cell cycle analysis Cells were treated with lobaplatin as indicated and then collected for cell cycle analysis. The cells were washed twice with ice-cold PBS and fixed with ice-cold 70% ethanol for 12 h at 4°C. Fixed cells were stained with 5 lg/mL propidium iodide solution with 200 lg/mL DNase-free RNase A at 37°C for 30 min and analyzed using a FACScan flow cytometer (BD Biosciences, USA).
Cell apoptosis assay
Cells were seeded in six-well plates at 5 9 10 5 cells/ well for 24 h and then treated with lobaplatin as indicated. Cell apoptosis was examined with PE Annexin V Apoptosis Detection Kit I according to the instruction provided by the manufacturer using a FACScan flow cytometer (BD Biosciences, USA). Data were presented as mean AE standard deviation (SD) from three independent experiments.
Cell proliferation assay Cell proliferation assay was performed according to the instruction provided by the manufacturer (Promega). Briefly, cells (5000 cells in 100 lL/well) were seeded in 96-well plates for 24 h and then treated with either vehicle control (DMSO) or lobaplatin at different concentrations (0, 1, 5, 10 and 25 lg/mL) for 24, 48 and 72 h. 20 lL CellTiter 96 AQ ueous One Solution was added to each well and incubated for 2 h at 37°C. The absorbance was read at 490 nm using a 96-well plate reader (BioTek).
Transwell cell migration assay
Transwell cell migration assay was performed according to previous reports with modification [20] . Briefly, 2 9 10 5 cells in 100 lL serum free medium was added to an 8.0-lm, 24-well plate upper chamber (Corning Life Sciences, NY, USA) and 600 lL medium containing 10% fetal bovine serum (FBS) was added to the bottom chamber. Cells were treated with lobaplatin for 24 h and fixed with 4% paraformaldehyde for 15 min. After washing with PBS, non-migrated cells in the upper chamber were scraped with a cotton swab. The migrated cells were stained with 0.5% crystal violet blue for 15 min and then washed with double-distilled H 2 O (ddH 2 O). Migrated cells in four randomly selected fields were counted and photographed using microscope. Data were presented as mean AE standard deviation (SD) from three independent experiments.
Western blotting
The Western blotting analysis was performed as described previously [21] . Briefly, cells were washed with ice-cold PBS and lysed with RIPA buffer (40 mM HEPES pH 8.0, 150 mM NaCl and 1% NP-40) supplemented with protease inhibitors (Complete Mini, Roche) and phosphatase inhibitor (phosphatase inhibitor cocktail set I and II, Millipore, Billerica, MA, USA). The protein concentration was measured using a Bradford Protein Assay Kit (Bio-Rad, USA). Equal amounts of protein from each sample were separated by SDS-PAGE gel and transferred to a PVDF (polyvinylidene difluoride) membrane (Bio-Rad). The membranes were blocked with 5% non-fat milk at room temperature for 1 h and then probed with specific primary antibodies overnight at 4°C. After incubation with secondary antibodies, the membranes were incubated with an enhanced chemiluminescence detection kit.
Real-time RT-PCR Total RNA was extracted using the RNeasy mini kit (Qiagen, Valencia, CA, USA) and the RNA concentration was measured using NanoDrop 2000 (Thermo Scientific, Waltham, MA, USA). The reverse transcription reaction was performed using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific). Real-time PCR was performed with the 7500 Fast Real-Time PCR system (ABI, USA). GAPDH was used as an internal control. Primer sequence: PSA-F, 5
Micrococcal nuclease (MNase) assay Cells were treated with lobaplatin for 24 h and then lysed in ice-cold NP-40 lysis buffer (10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 0.5% Nonidet P-40, 0.15 mM spermine and 0.5 mM spermidine.) for 10 min. Nuclei were isolated by centrifugation and resuspended in MNase digestion buffer (10 mM Tris-HCl (pH 7.4), 15 mM NaCl, 60 mM KCl, 1 mM CaCl2, 0.15 mM spermine and 0.5 mM spermidine) and digested with MNase for 5 min at room temperature. The reaction was stopped by MNase stop buffer (100 mM EDTA and 10 mM EGTA, pH 7.5). DNA was isolated by phenol/chloroform and separated on a 1% agarose gel.
Nude mouse xenograft assay 5 9 10 6 22Rv1 cells were suspended in 100 lL of RPMI 1640 medium and injected into the flanks of male nude mice (10 mice) to allow tumor formation. When the average tumor volume reached 100 mm 3 , mice were randomized and then treated with vehicle or lobaplatin (25 mg/kg bodyweight) via tail vein (5 mice for each group). Tumor size was measured every 3 days with a caliper, and the tumor volume was determined with the formula: a 9 b 2 9 0.52, where a is the longest diameter and b is the shortest diameter. At the end of the studies, mice were sacrificed and tumors were dissected and weighed. All care and treatment of experimental animals were conducted under a protocol approved by the ethic committee of LONGHUA Hospital Shanghai University of Traditional Chinese Medicine.
R E S U L T S
Lobaplatin triggered G2/M cell cycle arrest and cell apoptosis To investigate the cytotoxic effects of lobaplatin on prostate cancer cells, we first examined the cell cycle progression by flow cytometry analysis in the presence of lobaplatin. As shown in Figure 1a , treatment with lobaplatin for 24 h significantly arrested cell cycle in G2/M phases in a concentration-dependent manner in various prostate cancer cells, accompanied by reduction in the cell population in G1 phases. Next, we further assessed whether lobaplatin induced cell apoptosis. As shown in Figure 1b , treatment with lobaplatin for 48 h significantly induced cell apoptosis in a dosedependent manner. Consistently, the protein levels of apoptotic markers, including cleaved PARP and cleaved Caspase 3, were elevated upon lobaplatin treatment (Figure 1c) . Altogether, these data indicate that lobaplatin induces cell cycle arrest and cell apoptosis in prostate cancer cells. 
Lobaplatin inhibited proliferation of human prostate cancer cells in vitro
To explore the potential roles of lobaplatin on prostate cancer, we first performed MTS assay to examine the effects of lobaplatin on proliferation of prostate cancer cells. Similar to the anti-proliferation effects of enzalutamide, lobaplatin significantly inhibited proliferation of prostate cancer cells in a concentration-dependent and time-dependent manner (Figure 2a,b) . Moreover, we found that lobaplatin also significantly reduced colony formation of 22Rv1 and C4-2 cells in a concentrationdependent manner (Figure 2c,d) . These results suggest that prostate cancer cells are sensitive to lobaplatin treatment.
Lobaplatin impaired prostate cancer cell migration As most of metastatic prostate cancer is a lethal disease and now it lacks efficient drugs for treatment, we next explored whether lobaplatin could suppress prostate cancer cell migration, a critical step of cancer metastasis. Using the wound-healing assay, we found that compared with DMSO, cell migrates to the wound area was much slower in the presence of lobaplatin (Figure 3a,b) . Consistently, we performed transwell migration assay and found that lobaplatin significantly reduced cell migration (Figure 3c,d) . These results indicate that lobaplatin might be a potential drug for treatment metastatic prostate cancer by inhibiting cell migration.
Lobaplatin suppressed tumor growth in xenograft mouse model To further investigate whether lobaplatin inhibits tumor growth in vivo, 22Rv1 cells were injected into male nude mice to allowed tumor growth. Notably, lobaplatin could significantly retarded tumor growth compared with the control (Figure 4a-c) . At the end of the experiment, the mean tumor mass in the control group was 437.6 mg, whereas in the treatment group was 162.0 mg (P < 0.001). These results coherently support the notion that lobaplatin could inhibit t prostate tumorigenesis.
Lobaplatin attenuated AR and ERG signaling pathways Next, we further dissected the molecular mechanisms underlying the antitumor activity of lobaplatin on prostate cancer. Given the transcription factors, AR and ERG, are the major drivers of prostate cancer initiation and metastasis, we sought to examine the effects of lobaplatin on both AR and ERG signal pathways. Notably, treatment of lobaplatin significantly downregulated the mRNA levels of AR and ERG target genes, Role of lobaplatin on prostate cancer progression including PSA, TMPRSS2, MMP9, and ADAMTS1 (Figure 5a,b) . Consistently, the protein levels of AR, ERG, PSA, and c-MYC were dramatically decreased, whereas MDR1 was elevated, upon lobaplatin treatment (Figure 5c ). Moreover, lobaplatin rendered chromatin more sensitive to MNase digestion (Figure 5d ), indicating that lobaplatin might interfere the expression of key oncogenic genes through changing the chromatin structure. Altogether, our data suggest that lobaplatin suppresses prostate cancer progression by inhibiting cell proliferation and migration in part through impairing AR and ERG signaling pathways.
D I S C U S S I O N
Prostate cancer is the most common non-cutaneous cancer and the second second leading cause of cancer-related deaths in men [1, 3] . Despite the progression of early diagnosis for prostate cancer, more than 20% of prostate cancer patients will develop metastatic disease [22] . The androgen signaling pathway is an important axis responsible for prostate cancer progression, and therefore inhibition of AR signal by androgen deprivation is a currently common strategy for prostate cancer therapy [23] . The androgen receptor (AR) is a steroid hormone-dependent transcription factor that binds with its native ligands 5a-dihydrotestosterone (DHT) and translocates into nucleus to regulate the expression of specific genes [24] . AR has several splice variants and is frequently mutated or amplified in prostate cancer [25] . Studies have been
shown that AR can bind with different transcriptional co-activators, including BET proteins, to promote aggressive tumor [26] . Although inhibition of the androgen receptor by androgen deprivation therapy (ADT) has been shown encourage outcomes for prostate cancer treatment, more than 50% advanced prostate cancer becomes resistant to ADT within five years, known as hormone-refractory prostate cancer or castrate-resistant prostate cancer (CRPC) [27] . To this end, new hormonal agents (abiraterone and enzalutamide) and chemotherapeutic agents (docetaxel and cabazitaxel) have been developed and were effective in CRPC [28] . Therefore, chemotherapy is typically used when prostate cancer has spread outside the prostate gland and hormone therapy isn't working. However, prostate cancer ultimately develops resistance to these drugs and metastasis to other sites of our body. Thus, it is important to develop new antitumor drugs that not only inhibit tumor cell growth, but also suppress cell migration and invasion for prostate cancer therapy. Another prostate cancer major driver is ERG oncogene. In more than 50% prostate cancer, ERG gene fused to androgen-inducible TMPRSS2 gene promoter, resulting in the TMPRSS2-ERG gene fusion and aberrant overexpression of ERG oncoprotein with deletion of 46 or 99 amino acids at the N-terminal [12, 13] . Previous studies demonstrated that depletion of ERG significantly retards tumor growth in mice xenograft model [29] . Moreover, ERG transgenic mouse in combination with other genetic alterations such as PTEN loss could dramatically facilitate prostate tumorigenesis [30] . Thus, ERG can be a marker for diagnosis and prognosis, as well as a potential therapeutic target for prostate cancer [31] . Notably, recent studies showed that inhibition of ERG-interacting co-factors, including PARP1 and BET proteins, could suppress prostate cancer initiation and migration in preclinical models [26, 32] . However, further studies are required to show the antitumor effects of these inhibitors in clinical trials of prostate cancer.
Platinum-based drugs, including cisplatin, are widely used in treating human cancers [19] . Lobaplatin is a third-generation platinum anticancer drug with DNA alkylating activity, leading to GG and AG intrastrand cross-links [33] . It has been reported that lobaplatin triggers apoptosis and cell cycle arrest by affecting p53 and Rb signaling pathways in hepatocellular carcinoma [34] . Clinical trials of lobaplatin have also demonstrated well responses in ovarian cancer, breast cancer and small cell lung cancer [19] . In this study, we demonstrate that lobaplatin could inhibit prostate cancer in vitro and in vivo in part by suppressing both AR and ERG signaling pathways that are two major drivers of prostate cancer. Interestingly, although a previous study demonstrated that lobaplatin could induce c-MYC promoter activity [35] , our study showed that lobaplatin downregulated c-MYC expression in multiple prostate cancer cell lines, which may be attributed to the fact that c-MYC is a downstream target of AR and ERG in prostate cancer setting [29, 36] . Moreover, consistent with previous studies [37] [38] [39] , our results also demonstrated that lobaplatin treatment dramatically elevated MDR1 expression, indicating that combination of lobaplatin and MDR1 specific inhibitor might achieve better outcomes for prostate cancer therapy. Lastly, given the common effects of lobaplatin on the chromatin structure, it is also possible that lobaplatin may affect global gene expression to suppress prostate cancer development. Analysis of global gene expression profiling by microarray warrants a depth-study in the near future.
In conclusion, our present study showed that lobaplatin induced cell cycle arrest and apoptosis in prostate cancer cells. As a result, lobaplatin significantly inhibited cell proliferation, migration and tumor growth in vitro and in vivo. Mechanistically, AR and ERG activity dramatically decreased upon lobaplatin treatment. Altogether, these results demonstrate the antitumor activity of lobaplatin and provide a potential molecular mechanism and basis for using lobaplatin as a novel agent to treat prostate cancer. 
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